WO2009060083A2 - Utilisation d'un sarcosinate n-acylé en tant qu'agent contre l'adhésion microbienne - Google Patents

Utilisation d'un sarcosinate n-acylé en tant qu'agent contre l'adhésion microbienne Download PDF

Info

Publication number
WO2009060083A2
WO2009060083A2 PCT/EP2008/065173 EP2008065173W WO2009060083A2 WO 2009060083 A2 WO2009060083 A2 WO 2009060083A2 EP 2008065173 W EP2008065173 W EP 2008065173W WO 2009060083 A2 WO2009060083 A2 WO 2009060083A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
sarcosinate
composition
agents
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/065173
Other languages
English (en)
Other versions
WO2009060083A3 (fr
Inventor
Géraldine Lerebour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of WO2009060083A2 publication Critical patent/WO2009060083A2/fr
Anticipated expiration legal-status Critical
Publication of WO2009060083A3 publication Critical patent/WO2009060083A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • N-acylated sarcosinate as an agent against microbial adhesion
  • the present invention relates to the use of at least one N-acylated sarcosinate of formula (I), in a cosmetic composition as an agent for preventing or reducing the adhesion of microorganisms to the surface of the skin and/or of the mucosae, in particular to the surface of a healthy skin and/or of healthy mucosae.
  • healthy skin and/or healthy mucosae is intended to mean a skin and/or mucosae that do not present lesions and/or infections, in particular due to microorganisms.
  • It also relates to a cosmetic process aimed at preventing and/or reducing the adhesion of microorganisms on the surface of the skin and/or of the mucosae exhibiting an impaired barrier function, comprising the application, to the skin and/or the mucosae exhibiting an impaired barrier function, of a composition comprising at least one N-acylated sarcosinate of formula (I).
  • N-acylated sarcosinate of formula (I) for the preparation of a pharmaceutical composition for use in preventing and/or treating atopic dermatitis.
  • 'skin' is intended to mean in particular the skin and/or the scalp.
  • 'mucosa' is intended to mean in particular the vaginal mucosa.
  • Human skin is continuously populated by a multitude of different microorganisms (bacteria, yeast and fungi).
  • Commensal microorganisms living on or in the skin may be part of a microflora that is either resident (normal) or transient.
  • the resident microbial flora which is essential for healthy skin, is constituted mainly of staphylococci (Staphylococcus epidermis and Staphylococcus hominis), of corynebacteria, of gram+ propionibacteria such as Propionibacterium acnes, and also of a fungal flora mainly composed of Pityrosporum ovale. They are present in well-defined distribution profiles.
  • the transient microorganisms do not become solidly attached; they are incapable of multiplying and normally die within a few hours.
  • the anatomy and the physiology of the skin vary from one part of the body to the other and the resident microflora reflects these variations. Most of the skin bacteria are present on the superficial squamous epidermis, colonizing dead cells, and closely associated with the sebaceous and sweat glands. The excretions from these glands provide water, amino acids, urea, electrolytes and specific fatty acids that serve as nutritive elements mainly for Staphylococcus epidermidis and aerobic corynebacteria.
  • Skin disorders of the aesthetic type spots, body odours, in particular those from the axillary or perineal region or foot odour
  • pathological type folliculitis, pruritus, candidiasis, forms of dermatitis such as atopic dermatitis, seborrhoeic dermatitis, pityriasis versicolor, forms of dermatitis such as impetigo, superficial folliculitis, eczematous superinfections, dermatophytosis; mycosis; acne, in particular juvenile acne
  • Disorders related to hormone disturbances such as greasy skin, or an altered surface condition of the skin and/or of the mucosae (dry skin and/or scalp, sensitive skin and/or scalp) may also promote the development of saprophytic bacterial flora.
  • the pathogenic germs that are most well known are Pseudomonas aeruginosa (gram-), which is responsible for small spots, folliculitis, redness and pruritus, Candida albicans, which can cause inflammation of the corner of the lips, cutaneous candidiasis, pruritus, folliculitis and aphthae, Staphylococcus aureus, which can cause spots, folliculitis, impetigo, forms of dermatitis such as atopic dermatitis, psoriasis, neurodermatitis and furuncles, and group A Streptococcus, responding for impetigo.
  • Greasy or shiny skin an aesthetic disorder characterized by a sebum level of greater than 200 ⁇ g/cm 2 measured on the forehead, may also be a favourable terrain for the uncontrolled growth of saprophytic bacterial flora, such as P. acnes, and can bring about acneic lesions.
  • yeasts Pityrosporum ovale and Pityrosporum orbiculare commonly associated with the formation of dandruff.
  • Atopic dermatitis also known as atopic dermitis or atopic eczema, is a condition of the epidermis which affects a large number of individuals, including children and adolescents. In Europe, approximately 10% of children and 20% of the population are affected, with an increase in cases over the last few decades.
  • Atopic dermatitis generally occurs in individuals genetically predisposed to atopy and to the manifestations thereof, namely asthma, allergic rhinitis and allergies. This chronic skin disease is due to complex interactions between the genetic predispositions of the individual and environmental factors.
  • Atopic dermatitis is characterized by the barrier function breaking down and by the skin drying out - the term atopic dry skin is used. It is often associated with an invasion by S. aureus, in particular in oozing lesions, such as the fold of the elbow and on the forehead, whereas this germ is more or less absent in healthy individuals, in whom, as a general rule, the bacterial flora is, for example, virtually nonexistent in the fold of the elbow, and essentially amounts to S. epidermis and Propionibacterium. sp. in the highly sebaceous region of the forehead.
  • atopic skin may be related to a decrease in the synthesis of ceramides 1 and/or 3, as is in particular reported in Imokawa et al., in J Invest Dermatol, 96 (4): 523-6, 1991 , and Di Nardo et al. in Acta Derm Venereol, 78 (1 ): 27-30, (1998).
  • Sensitive skin which generally exhibits dry skin and an interruption of the barrier function, is also more vulnerable to colonization by microorganisms such as S. aureus.
  • antibiotics or bactericides In order to combat these microorganisms, it is common practice to use antibiotics or bactericides. However, the use of these compounds poses the problem of the nonspecificity of action which targets without distinction the pathogenic flora and the resident flora, the problem of the risk of bacterial resistance emerging, and also problems of skin tolerance (irritations, allergies, etc.).
  • skin disorders related to the adhesion of microorganisms and/or the problems of skin tolerance related to the treatments for said disorders are particularly critical in individuals with skin and/or mucosae having an impaired barrier function and/or dryness of the skin.
  • Atopic skin is characterized by the barrier function breaking down and the skin drying out - the terms atopic dry skin or atopic dermatitis are used.
  • Atopic dermatitis is the first symptom of atopy and it is often associated with an invasion by S. aureus, in particular in oozing lesions, such as the fold of the elbow and on the forehead, whereas this germ is more or less absent in healthy individuals, in whom, as a general rule, the bacterial flora is, for example, virtually nonexistent in the fold of the elbow, and essentially amounts to S. epidermis and Propionibacterium. sp. in the highly sebaceous region of the forehead.
  • Immunodeficiency promotes the abnormal development of ordinarily non-pathogenic microbes, which are then responsible for "opportunistic" diseases, and also the more frequent and more serious development of infection with pathogenic germs. It is also known practice to reduce or prevent the colonization of surfaces, such as the teeth, the skin and/or the mucosae, by pathogenic germs by preventing their attachment to these supports.
  • the compounds used as anti-adhesion agents described in the prior art are either silicones (WO-99/62475) or carbohydrates and carbohydrate derivatives, such as those described in patent application WO-96/23479, or plant oils as described in patent application EP-1 133 979.
  • N-acylated sarcosinate of formula (I), in particular a sodium lauroyl sarcosinate makes it possible to significantly reduce the adhesion of microorganisms to the surface of the skin and/or of the mucosae, in particular the adhesion of Staphylococcus aureus, and to thus prevent the proliferation of potentially pathogenic germs, in the absence of antibiotic, bactericidal or fungicidal agents, and without it being necessary to use a large amount of preservatives.
  • sodium lauroyl sarcosinate as a surfactant or dispersant in cleansing and/or makeup-removing compositions is known from the prior art.
  • X is a cation chosen from the ions of the alkali metals sodium (Na) or potassium (K), and an ammonium group, in a composition, as an agent for preventing or reducing the adhesion of microorganisms to the surface of the skin and/or of the mucosae.
  • the composition is a cosmetic composition.
  • the N-acylated sarcosinate of formula (I) is used in the composition as unique agent for preventing or reducing the adhesion of microorganisms to the surface of the skin and/or of the mucosae.
  • the N-acylated sarcosinate of formula (I) is not reacted with an other compound before introduction into said composition.
  • the N-acylated sarcosinate of formula (I) is sufficient at itself for preventing or reducing the adhesion of microorganisms to the surface of the skin and/or of the mucosae.
  • N-acylated sarcosinates use may be made of ammonium lauroyl sarcosinate, potassium lauroyl sarcosinate, sodium lauroyl sarcosinate, sodium palmitoyl sarcosinate and sodium myristoyl sarcosinate.
  • the N-acylated sarcosinate of formula (I) used according to the invention is a sodium N-acylated sarcosinate.
  • sodium lauroyl sarcosinate sold under the name Oramix L30 ® by the company SEPPIC
  • the sodium myristoyl sarcosinate sold under the name Nikkol Sarcosinate MN ® by the company Nikko Chemicals
  • the sodium palmitoyl sarcosinate sold under the name Nikkol sarcosinate PN ® by the company Nikko Chemicals.
  • sodium lauroyl sarcosinate will be used.
  • a preferred N-acylated sarcosinate according to the invention is the sodium lauroyl sarcosinate sold under the name Oramix L30 ® by the company SEPPIC, comprising 30%, with respect to active material, of sodium lauroyl sarcosinate in an aqueous solution.
  • preventing or reducing the adhesion of microorganisms should be understood to mean that the N-acylated sarcosinate of formula (I) according to the invention or the composition containing same may be used both preventative ⁇ , for its ability to completely or partially prevent the adhesion of microorganisms, and curatively, for its ability to facilitate the detachment of microorganisms.
  • N-acylated sarcosinate of formula (I) is for use in preventing or reducing the adhesion of S. aureus to the surface of the skin and/or of the mucosae.
  • the N-acylated sarcosinate of formula (I) is for use in preventing and/or reducing unpleasant body odours.
  • the N-acylated sarcosinate of formula (I) is for use in preventing and/or reducing dandruff states.
  • the amount of N-acylated sarcosinate of formula (I) used in the composition depends, of course, on the desired effect and may therefore vary to a large extent.
  • the N-acylated sarcosinate of formula (I) may be present in the composition in an amount ranging from 0.001 % to 10% by weight, relative to the total weight of the composition, preferably ranging from 0.01% to 5% by weight, and preferentially ranging from 0.1 % to 3% by weight, and still preferably from 0.1 % to 2% by weight.
  • the invention also relates to the use of at least one N-acylated sarcosinate of formula (I), for the preparation of a pharmaceutical composition for use in preventing and/or treating skin disorders related to the adhesion of microorganisms to the surface of the skin and/or of the mucosae.
  • the N-acylated sarcosinate of formula (I) is used as an agent for preventing or reducing the adhesion of microorganisms to the surface of the skin and/or of the mucosae.
  • the invention relates to the use of at least one N-acylated sarcosinate of formula (I), for the preparation of a pharmaceutical composition for use in preventing and/or treating skin disorders related to the adhesion of S. aureus to the surface of the skin and/or of the mucosae.
  • the invention relates to the use of at least one N-acylated sarcosinate of formula (I), for the preparation of a pharmaceutical composition for use in preventing and/or treating atopy, in particular atopic dermatitis.
  • the invention relates to the use of at least one N-acylated sarcosinate of formula (I), for the preparation of a pharmaceutical composition for use in preventing and/or treating mycosis.
  • the invention relates to the use of at least one N-acylated sarcosinate of formula (I), for the preparation of a pharmaceutical composition for use in preventing and/or treating acne, in particular juvenile acne.
  • the N-acylated sarcosinate of formula (I) is the only anti-adhesion agent present in the composition.
  • compositions used according to the invention may in particular constitute cosmetic or dermatological compositions.
  • they contain a physiologically acceptable medium.
  • physiologically acceptable medium is herein intended to mean a medium compatible with the skin and/or the mucosae, and possibly with the lips, the scalp, the eyelashes, the eyes and/or the hair.
  • This physiologically acceptable medium may be more particularly constituted of water and, optionally, of a physiologically acceptable organic solvent chosen, for example, from lower alcohols containing from 1 to 4 carbon atoms, such as ethanol, isopropanol, propanol or butanol; polyethylene glycols having from 6 to 80 ethylene oxide units; polyols, such as propylene glycol, isoprene glycol, butylene glycol, glycerol or sorbitol.
  • the physiologically acceptable medium of the composition according to the invention has a pH compatible with the skin, and preferably ranging from 3 to 8, and better still from 5 to 7.
  • the compositions used in the present invention also comprise an oil, which provides in particular comfort and softness during application to the skin.
  • the amount of oil may range, for example, from 2% to 70% by weight, and preferably from 5% to 30% by weight, relative to the total weight of the composition.
  • the oily phase of the emulsion may also contain gums such as silicone gums, resins and waxes.
  • composition containing an oily phase may be in the form of a water-in-oil (W/O) or oil-in- water (O/W) emulsion. According to one preferred embodiment, it is in the form of a water-in- oil emulsion.
  • the composition also contains at least one adjuvant chosen from gelling agents, moisturizers, preservatives, antioxidants, solvents, fragrances, fillers, screens, pigments, chelating agents, odour absorbers, dyestuffs and matting agents, and mixtures thereof.
  • adjuvant chosen from gelling agents, moisturizers, preservatives, antioxidants, solvents, fragrances, fillers, screens, pigments, chelating agents, odour absorbers, dyestuffs and matting agents, and mixtures thereof.
  • compositions of the invention may also contain adjuvants that are customary in the cosmetics or dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, screens, bactericides, odour absorbers, dyestuffs or salts.
  • adjuvants that are customary in the cosmetics or dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, screens, bactericides, odour absorbers, dyestuffs or salts.
  • the amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01% to 20% of the total weight of the composition, and preferably from 0.01 % to 10% of the total weight of the composition.
  • these adjuvants may be introduced into the fatty phase, into the aqueous phase and/or into
  • compositions used according to the invention may contain other agents for preventing the adhesion of bacteria to the surface of the skin, such as the oils and the fatty substances described in patent application EP-1 313 086, or the alkoxylated plant oils described in patent application FR-2 832 057. They may also advantageously contain other active agents chosen from desquamating agents, moisturizing agents and antiseborrhoeic agents, and mixtures thereof.
  • the N-acylated sarcosinate of formula (I) is the only agent against microorganism adhesion present in the composition according to the invention.
  • active agents for caring for the skin and/or the mucosae that can be used in the composition of the invention, mention may in particular be made of moisturizing agents, desquamating agents, agents for improving the barrier function, depigmenting agents, dermodecontracting agents, anti-glycation agents, agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing degradation thereof, agents for stimulating fibroblast or keratinocyte proliferation and/or keratinocyte differentiation, agents for promoting maturation of the horny envelope, NO-synthase inhibitors, peripheral benzodiazepine receptor (PBR) antagonists, agents for increasing sebaceous gland activity, agents for stimulating the energy metabolism of cells, tensioning agents, liporestructuring agents, slimming agents, agents for promoting skin microcirculation, calmatives and/or anti- irritants, sebo-regulating agents or antiseborrhoeic agents, astringents, healing agents, antiinflammatories and anti-
  • compositions used may also comprise at least one organic photoprotective agent and/or at least one inorganic photoprotective agent active in the UVA and/or UVB range (absorbers), which are water-soluble or liposoluble or else insoluble in the cosmetic solvents commonly used.
  • the preferred organic photoprotective agents are chosen from ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazolesulphonic acid, benzophenone-3, benzophenone-4, benzophenone-5, 4-methylbenzylidenecamphor, terephthalylidenedicamphorsulphonic acid, disodium phenyl dibenzimidazole tetrasulphonate, 2,4,6-tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine, anisotriazine, ethylhexyl triazone, diethylhexyl butamido triazone, methylenebisbenzotriazolyltetramethylbutylphenol and drometrizole trisiloxane, and mixtures thereof.
  • the inorganic photoprotective agents are chosen from pigments or alternatively nanopigments (average size of primary particles: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm) of metal oxides which are coated or uncoated, for instance nanopigments of titanium oxide (amorphous or crystalline in rutile and/or anatase form), of iron oxide, of zinc oxide, of zirconium oxide or of cerium oxide, which are all UV photoprotective agents well known per se.
  • Conventional coating agents are, moreover, alumina and/or aluminium stearate.
  • Such coated or uncoated metal oxide nanopigments are in particular described in patent applications EP518772 and EP518773.
  • the photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.1 % to 20% by weight, relative to the total weight of the composition, and preferably ranging from 0.2% to 15% by weight, relative to the total weight of the composition.
  • gelling agents mention may, for example, be made of cellulose derivatives such as hydroxyethylcellulose and alkylhydroxyethylcelluloses such as cetylhydroxyethylcellulose; algal derivatives such as satiagum; natural gums such as tragacanth or guar gum; synthetic polymers such as carboxyvinyl polymers or copolymers, and in particular those sold under the names Carbopol R by the company Goodrich or Synthalen R by the company 3V SA.
  • the proportion of gelling agent preferably ranges from 0.1% to 2% of the total weight of the composition.
  • compositions used according to the invention may be more or less fluid and may have the appearance of a white or coloured cream, an ointment, a milk, a lotion, a gel, a serum, a paste or a mousse. They may optionally be applied to the skin in the form of an aerosol. They may also be in solid form, and for example in the form of a stick.
  • the composition is in the form of a lotion, an aqueous gel, a serum, an emulsion or a dispersion of lipid vesicles.
  • it is in the form of a lotion or an aqueous gel.
  • N-acylated sarcosinates of formula (I) according to the invention also have the advantage, compared with other known anti-adhesion compositions, of having good water- solubility, allowing them to be used, even at a high concentration, in aqueous compositions of the lotion, makeup-removing water or tonic type, or else compositions for body care and/or cleansing, such as shower gels, shampoos or intimate gels.
  • compositions according to the invention are in particular compositions for caring for and/or for cleansing/removing makeup from the skin and/or the mucosae.
  • the composition is a skin care and/or treatment composition.
  • N-acylated sarcosinate of formula (I) may also be used in the context of the present invention in antisun products, in makeup products such as foundations, lipsticks, mascaras or face powders, in body products, and/or in deodorants.
  • the composition is a care composition.
  • the composition is a cleansing and/or makeup-removing composition.
  • One aspect of the invention relates to the use of the compound of formula (I) in a care and/or cleansing composition for dry skin, advantageously a care composition.
  • Another aspect of the invention relates to the use of the compound of formula (I) in a care and/or cleansing composition for fragile skin, advantageously a care composition.
  • Another aspect of the invention relates to the use of the compound of formula (I) in a care and/or cleansing composition for weakened skin, advantageously a care composition.
  • Another aspect of the invention relates to the use of the compound of formula (I) in a care and/or cleansing composition for sensitive skin, advantageously a care composition.
  • Another aspect of the invention relates to the use of the compound of formula (I) in a care and/or cleansing composition for immunodeficient skin, advantageously a care composition.
  • Another aspect of the invention relates to the use of the compound of formula (I) in a care and/or cleansing composition for aggravated skin, advantageously a care composition.
  • a subject of the present invention is also the cosmetic use of the N-acylated sarcosinate of formula (I), as an agent for reducing unpleasant body odours and/or for body hygiene care.
  • said N-acylated sarcosinate of formula (I) is the only anti-adhesion agent present in said composition.
  • for body hygiene care is intended to mean a substance intended to be brought into contact with the various superficial parts of the human body and/or with the mucosae and/or with the teeth, for the purpose of cleansing them, of protecting them, of keeping them in good condition, of modifying their appearance, of fragrancing them or of correcting their odour.
  • the invention also relates to a cosmetic process aimed at preventing and/or reducing the adhesion of microorganisms on the surface of the skin and/or of the mucosae exhibiting an impaired barrier function, comprising the application, to the skin and/or the mucosae exhibiting an impaired barrier function, of a composition comprising at least one N-acylated sarcosinate of formula (I) as defined above.
  • composition may be applied to individuals with dry skin.
  • it may be applied to individuals with fragile or delicate skin, in particular babies.
  • the composition is applied to individuals with weakened skin, such as individuals whose cutaneous aqueous-lipid film is impaired, in particular individuals over the age of 60.
  • the composition is applied to individuals with sensitive skin.
  • the composition is applied to individuals with aggravated skin, in particular shaved skin.
  • Another aspect of the invention relates to a cosmetic process aimed at preventing and/or reducing the adhesion of microorganisms to the surface of the skin and/or of mucosae of an immunodeficient individual, comprising the application, to the skin and/or the mucosae of said individuals, of a composition comprising at least one N-acylated sarcosinate of formula (I) as defined above.
  • the composition to the skin and/or the mucosae of said individuals is a cosmetic composition.
  • Another aspect of the invention relates to a process for reducing unpleasant body odours, comprising the topical application to the skin, in particular of the armpits, the perineal region or the feet, of a composition comprising, in a physiologically acceptable medium, as sole anti-adhesion agent, at least one sarcosinate of formula (I) as defined above.
  • the process for reducing unpleasant body odours is a cosmetic and/or non- therapeutic process
  • the composition applied to the skin is a cosmetic composition.
  • the cosmetic processes according to the present invention comprise the application of a composition according to the present invention to a healthy skin and/or of healthy mucosae.
  • healthy skin and/or healthy mucosae is intended to mean a skin and/or mucosae that do not present lesions and/or infections, in particular due to microorganisms..
  • Example 1 Microbial anti-adhesion test
  • the reconstructed epidermis is brought into contact, for 2 hours, with 0.5% of said aqueous solution comprising 30%, with respect to active material, of sodium lauroyl sarcosinate at 37 ⁇ O.
  • the bacterial suspension is emptied out and five rinses are performed with 1 ml of sterile distilled water.
  • the reconstructed epidermis detached from its support is then ground in 18 ml of tryptone salt using an automated processor.
  • This suspension is then diluted ten-fold in the tryptone salt, and 1 ml of the dilution is then inoculated into 15 ml of trypticase soybean agar and incubated for 24 hours at 37°C. The adherent and viable cells are then counted.
  • the germs are counted by ten-fold dilution in tryptone salt and inoculation, using a scraper, of 100 ⁇ l on trypticase soybean agar. The colonies are counted after incubation for 24 hours at 37 ⁇ .
  • the quantitative results correspond to a reduction in the decimal logarithm of the mean number of viable Staphylococcus aureus adherent on the reconstructed epidermis after treatment with the sodium lauroyl sarcosinate solution, relative to the decimal logarithm of the mean number of viable staphylococcus aureus adherent on the reconstructed epidermis after treatment with water under the same conditions.
  • the qualitative results are expressed by a variant term as a function of the values of Log reduction of the adhesion of the germs after 24 hours relative to the same test using water: the result obtained shows that the sodium lauroyl sarcosinate has an excellent bacterial anti- adhesion activity, better even than branched Ci 2 -Ci 3 dialcohol tartrate. results better than those obtained with water pro-adhesion results identical to those obtained with water no effect between 0.5 and 1 log reduction relative to water poor between 1 and 1 .5 log reduction relative to water moderate 1.5 and 2 log reduction relative to water good 2 log or more reduction relative to water excellent
  • sodium lauroyl sarcosinate has excellent efficacy with respect to the adhesion of S. aureus, even better than the efficacy of branched Ci 2 -Ci 3 dialcohol tartrate.
  • Example 2 Formulation examples
  • Liquid petroleum jelly 1 1 % PEG- 100 stearate 1.5%
  • This milk is suitable for individuals with dry and/or sensitive skin and can be used at a rate of one daily application to the body, for a moisturizing and protective effect.
  • This liquid soap can be used daily on individuals with dry skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur l'utilisation cosmétique d'un sarcosinate N-acylé de formule (I) comme agent pour prévenir ou réduire l'adhésion de microorganismes à la surface de la peau et/ou des muqueuses, en particulier de Staphylococcus aureus. L'invention porte également sur un procédé cosmétique visant à prévenir et/ou réduire l'adhésion de microorganismes à la peau présentant une fonction de barrière affectée, comprenant l'application, à la peau de sujets présentant une fonction de barrière affectée, d'une composition comprenant au moins un sarcosinate de formule (I). L'invention porte également sur l'utilisation d'au moins un sarcosinate de formule (I), pour la préparation d'une composition pharmaceutique destinée à être utilisée dans la prévention et/ou le traitement d'une dermatite atopique.
PCT/EP2008/065173 2007-11-08 2008-11-07 Utilisation d'un sarcosinate n-acylé en tant qu'agent contre l'adhésion microbienne Ceased WO2009060083A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0758875 2007-11-08
FR0758875A FR2923383B1 (fr) 2007-11-08 2007-11-08 Utilisation d'un sarcosinate n-acyle comme agent anti-adhesion microbienne.
US98742507P 2007-11-13 2007-11-13
US60/987,425 2007-11-13

Publications (2)

Publication Number Publication Date
WO2009060083A2 true WO2009060083A2 (fr) 2009-05-14
WO2009060083A3 WO2009060083A3 (fr) 2010-12-23

Family

ID=39591644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/065173 Ceased WO2009060083A2 (fr) 2007-11-08 2008-11-07 Utilisation d'un sarcosinate n-acylé en tant qu'agent contre l'adhésion microbienne

Country Status (2)

Country Link
FR (1) FR2923383B1 (fr)
WO (1) WO2009060083A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119326742A (zh) * 2024-12-20 2025-01-21 四川大学华西医院 肌氨酸作为唯一活性成分在制备防治肥胖和/或高血脂症的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2901399A (en) * 1955-05-20 1959-08-25 Bristol Myers Co Therapeutic preparations for topical application to the skin
DE2234399A1 (de) * 1972-07-17 1974-01-31 Thomae Gmbh Dr K Hautschutzmittel
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
FR2766366B1 (fr) * 1997-07-24 2000-02-11 Seppic Sa Utilisation d'au moins un lipoaminoacide en tant qu'antagoniste de la substance p dans une formulation cosmetique pour apaiser et/ou proteger tous les types de peaux et, notamment, les peaux sensibles
WO2002013776A2 (fr) * 2000-08-11 2002-02-21 The Procter & Gamble Company Procede assurant une meilleure application desodorisante sous les bras
US20050037039A1 (en) * 2003-08-12 2005-02-17 Yarbrough William M. Composition for treatment of tinea pedis and method of use
EP1656128A4 (fr) * 2003-08-12 2007-02-28 William M Yarbrough Traitement de l'acne simple et procede d'utilisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119326742A (zh) * 2024-12-20 2025-01-21 四川大学华西医院 肌氨酸作为唯一活性成分在制备防治肥胖和/或高血脂症的药物中的用途

Also Published As

Publication number Publication date
WO2009060083A3 (fr) 2010-12-23
FR2923383A1 (fr) 2009-05-15
FR2923383B1 (fr) 2010-03-19

Similar Documents

Publication Publication Date Title
CN113518614B (zh) 脂肪酸酯及其组合物的抗菌活性
JP4904811B2 (ja) α，α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤
JPH11322591A5 (fr)
US20200222358A1 (en) Topical dermatologic acne treatment cream composition and method of manufacture
JP2014521671A (ja) 皮膚および毛髪の外観を改善するためのスフィンガニンの使用
WO2003002074A1 (fr) Compositions en emulsion
ES2220019T3 (es) Uso de al menos un hidroxiestilbeno como agente disminuidor de la adhesion de los microorganismos.
ES2270314T3 (es) Utilizacion cosmetica de fitantriol como un agente para evitar o reducir la adhesion de los microorganismos a la superficie de la piel y/o de las mucosas.
US11306054B2 (en) Propanediol monoacetate mononitrate
JP2008069075A (ja) 皮膚外用組成物
EP0909557B1 (fr) Utilisation du miel en tant qu'agent diminuant l'adhésion des micro-organismes
US20020164360A9 (en) Use of polyamino acid derivatives to treat seborrhoea and the associated skin disorders
US20240058252A1 (en) Cosmetic method and composition based on short-chain fructooligosaccharides and a native starch
JP3658626B2 (ja) 化粧品および医薬部外品
JP5264829B2 (ja) 防腐殺菌剤及び化粧料組成物
WO2016033899A1 (fr) Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu
JPH03112912A (ja) 化粧料組成物
EP3485869B1 (fr) Utilisation de phytantriol comme agent antimicrobien dans la conservation d'une composition
WO2009060083A2 (fr) Utilisation d'un sarcosinate n-acylé en tant qu'agent contre l'adhésion microbienne
US20050131077A1 (en) Preventing or reducing the adhesion of microorganisms with phytanetriol
JPH0977653A (ja) 化粧料
KR20030026065A (ko) 2-에틸-1,3-헥산디올을 유효성분으로 하는 외용제용보존제 및 이를 이용한 외용제 조성물
KR20090001268A (ko) 백리향유를 포함하는 여드름 치료용 화장료 조성물
KR20090071529A (ko) 비타민 케이1 또는 비타민 케이3를 유효 성분으로 하는 항균 및 항진균 활성을 가지는 화장료 조성물
KR102571226B1 (ko) 글루코노락톤 및 클림바졸을 유효성분으로 포함하는 두피 상태 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847375

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08847375

Country of ref document: EP

Kind code of ref document: A2